HEMAB THERAPEUTICS HOLDINGS
COAGNASDAQTrading Snapshot
- Day Range
- $286.08 – $290.16
- 52-Week Range
- $23.00 – $55.42
- Volume
- $2.45B
- Avg Volume
- $2.12B
- Shares Outstanding
- 46.7M
- Next Earnings
- Nov 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $112M
- Last Q Revenue
- $30M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own COAG
- ✓High-growth profile — revenue up +3.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 40% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
HEMAB THERAPEUTICS HOLDINGS
COAG
StockOtter · stockotter.spaceAbout HEMAB THERAPEUTICS HOLDINGS
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
HEMAB THERAPEUTICS HOLDINGS tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift COAG price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
HEMAB THERAPEUTICS HOLDINGS announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.